Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Richard Forth"'
Autor:
William Busse, David Stempel, Bhumika Aggarwal, Isabelle Boucot, Richard Forth, Ibrahim Raphiou, Klaus F. Rabe, Helen K. Reddel
Publikováno v:
The journal of allergy and clinical immunology. In practice. 10(7)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a396e01842523f4745f07d80733cce74
https://pubmed.ncbi.nlm.nih.gov/35413473
https://pubmed.ncbi.nlm.nih.gov/35413473
Autor:
Ibrahim Raphiou, Isabelle Boucot, Richard Forth, William W. Busse, Helen K. Reddel, Bhumika Aggarwal, David A. Stempel, Klaus F. Rabe
Publikováno v:
Monitoring airway disease.
Background: This analysis from the 6-month AUSTRI study (GSK115359, n=11,679) explored the rate and heterogeneity of severe exacerbations with fluticasone propionate (FP) alone compared with FP plus salmeterol (FSC) in patients aged ≥12 years with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97cf7a1ec11b0a1f1714e8ded4b4be61
https://doi.org/10.1183/13993003.congress-2021.pa3716
https://doi.org/10.1183/13993003.congress-2021.pa3716
Autor:
Neil Barnes, Loretta Jacques, Edward Kerwin, Louisa Yates, David Leather, Michael Gibbs, Richard Forth
Publikováno v:
Journal of Asthma. 55:890-897
Objective: Symptoms, including night-time awakenings, affect the quality of life of people with asthma. Fluticasone furoate/vilanterol (FF/VI) reduces exacerbations, improves lung function, and rescue-free and symptom-free 24-hour periods in patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1dc19c2a5bd675648e3a8f6d785ecae
https://doi.org/10.1080/02770903.2017.1362429
https://doi.org/10.1080/02770903.2017.1362429
Autor:
David S. Pearlman, John M. Weiler, Loretta Jacques, Karen Dunn, Carol Nunn, Sarah West, Paul M. O'Byrne, Neil Martin, Richard Forth
Publikováno v:
The Journal of asthma : official journal of the Association for the Care of Asthma. 57(4)
Objective: To investigate whether once-daily (OD) fluticasone furoate (FF)/vilanterol (VI) provides greater long-term protection from postexercise fall in forced expiratory volume in 1 s (FEV1) than twice-daily (BD) fluticasone propionate (FP) in pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75269f246f26ca898c60c9305d05290f
https://pubmed.ncbi.nlm.nih.gov/30795705
https://pubmed.ncbi.nlm.nih.gov/30795705
Autor:
Eric D. Bateman, Ashley Woodcock, Carol Nunn, David I. Bernstein, Paul M. O'Byrne, Richard Forth, Loretta Jacques, William T Toler
Publikováno v:
Journal of Asthma. 52:1073-1083
Fluticasone furoate (FF; inhaled corticosteroid) combined with vilanterol (VI; long-acting beta(2) agonist) is a once-daily therapy for asthma and chronic obstructive pulmonary disease. This 12-week phase III study compared the efficacy and safety of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33b1bd9011339556fa19aa5388bbd50e
https://doi.org/10.3109/02770903.2015.1056350
https://doi.org/10.3109/02770903.2015.1056350
Autor:
William W. Busse, Richard Forth, Ashley Woodcock, Loretta Jacques, E.D. Bateman, Paul M. O'Byrne, Hilary Medley, Jan Lötvall
Publikováno v:
Allergy
Background Inhaled glucocorticosteroids (ICS) are the mainstay of treatment in asthma. Fluticasone furoate (FF) is a novel, once-daily ICS asthma therapy. This study investigated the efficacy and safety of FF 50 mcg in patients with mild-to-moderate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c55af534539b6ac41a972b74a3d8fdb
https://doi.org/10.1111/all.12480
https://doi.org/10.1111/all.12480
Autor:
Loretta Jacques, William W. Busse, Edward Kerwin, Paul M. O'Byrne, Sally Stone, Jan Lötvall, Eugene R. Bleecker, Eric D. Bateman, Richard Forth, Ashley Woodcock
Publikováno v:
Respiratory Medicine. 108(1):41-49
SummaryInhaled corticosteroids (ICSs) improve asthma disease control; once-daily ICS administration may have advantages for patients. Our objective was to assess the efficacy and safety of the novel ICS fluticasone furoate (FF) over 24 weeks versus p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a03acc6396bb86ae9274158578ade600
Objective: We aimed to demonstrate non-inferiority of once-daily fluticasone furoate/vilanterol 100/25 µg (FF/VI) to twice-daily fluticasone propionate/salmeterol 250/50 µg (FP/SAL) in adults/adolescents with asthma well controlled on inhaled corti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7c826fcaccdb18bccce8566995be013
Autor:
Loretta Jacques, William W. Busse, Eric D. Bateman, Eugene R. Bleecker, Richard Forth, Brett Haumann, Jan Lötvall, Angela Davis, Ashley Woodcock
Publikováno v:
Thorax. 67:35-41
Fluticasone furoate (FF) is a novel inhaled corticosteroid with 24 h activity. FF is being developed as a once-daily treatment in combination with the long-acting β(2) agonist vilanterol trifenatate for asthma and chronic obstructive pulmonary disea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9fcfdb380f9efb001983aae476c69a0
https://doi.org/10.1136/thoraxjnl-2011-200308
https://doi.org/10.1136/thoraxjnl-2011-200308
Publikováno v:
5.1 Airway Pharmacology and Treatment.
Rationale: The efficacy of FF and FF/VI have been studied in moderate/severe asthma. This analysis examined the effect of baseline eos level on response to different doses of FF and FF/VI. Methods: In post-hoc analyses of 2 studies (Woodcock A. et al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e2b3edade1b6e4fab8a8af14b2a29457
https://doi.org/10.1183/13993003.congress-2015.pa2956
https://doi.org/10.1183/13993003.congress-2015.pa2956